Cancer treatment developer Immunogen Inc. said Tuesday it will receive $20 million from Eli Lilly and Co. and could earn about $200 million in milestone payments under a collaboration agreement with the Indianapolis drugmaker.
Rolls-Royce Corp. began moving employees to its new downtown office building on Monday—a shift an IUPUI analyst projected could generate $510 million in annual economic activity.
The $1 million grant from the Arkansas-based Walton Family Foundation will fund a team that will open its first charter school in the 2013-2014 school year as part of what the group hopes will become a network of high-performing charter schools.
The honorees include business leaders, former U.S. presidents, famous novelists, a Shawnee chief and a feminist pioneer.
The federal judge said class counsel achieved “fabulous results with incredible efficiency” and that he had never been more proud of his profession in his 36-year legal career.
Eli Lilly and Co. stock rose to a one-month high Tuesday after an analyst said the possible success of the company’s experimental Alzheimer’s drug could double the share price.
A plan to offer a 10-year tax abatement worth $23 million for Rolls-Royce Corp. to redevelop two plants on the west side and move thousands of office workers into downtown’s Faris campus is scheduled for an initial hearing Wednesday.
Marvin White, system vice president and CFO of St. Vincent Health, is a finalist in the not-for-profit category.
Kristin Jones’ Nov. 26 column, “Patent reform is mixed bag for life sciences,” offered views on the impact of the new patent law, the America Invents Act, on large and small life sciences companies in Indiana.
Takeda Pharmaceutical Co. and marketing co-partner Eli Lilly and Co. may face as many as 10,000 lawsuits in U.S. courts over allegations that their Actos diabetes drug causes bladder cancer.
Indianapolis-based Eli Lilly and Co. recently rejected CVS Caremark’s demands for big price discounts on its insulins, leading CVS to kick Lilly’s insulins off its list of recommended drugs.
Indianapolis-based Eli Lilly and Co. is one of several Western pharmaceutical firms that see China as a linchpin of growth in coming years, due to patent expirations and a slowdown in government reimbursements for prescription medicines in the U.S. and European markets.
Samy Meroueh, a professor of biochemistry and molecular biology at the Indiana University School of Medicine, will receive $720,000 over a four-year period from the American Cancer Society to fund his cancer research. Meroueh’s research focuses on uPAR, a cell surface receptor that exists only in cancer cells that metastasize, making it an excellent target for the development of drugs. Metastasis, or the spreading of cancer from one organ to another, is the main reason that more than 90 percent of patients succumb to cancer, according to Meroueh. With earlier funding from the National Institutes of Health, Meroueh’s lab in Indianapolis has identified small molecules that attach to uPAR on the surface of cancer cells in metastatic tumors. He is now concentrating his research on two experimental compounds to examine their ability to block metastasis of breast cancer in mice. Meroueh hopes to later link his compounds to existing chemotherapy agents to deliver them directly to cancer cells, while sparing healthy cells.
Eli Lilly and Co. has joined a race to launch a new class of drugs to lower heart disease risk. An experimental drug under development by Lilly doubled levels of good cholesterol in a Phase 2 clinical trial, according to Bloomberg News. Good cholesterol, or HDL, sweeps the bad form of the fatty substance, called LDL, out of arteries, helping to reduce clogs. Lilly’s drug, called evacetrapib, boosted HDL as much as 129 percent and lowered bad cholesterol as much as 36 percent, the Indianapolis-based drugmaker reported on Nov. 15. Two other companies—New Jersey-based Merck & Co. Inc. and Switzerland-based Roche Holdings AG, have already moved similar drugs to the third and final phase of human trials, according to Bloomberg. Both drugs are predicted to be blockbusters with more than $5 billion in annual sales if they are approved. All three rivals aim to avoid the toxicity seen with a previous good cholesterol drug from New York-based Pfizer Inc. that was abandoned in 2006 after it triggered deaths in a study.
The St. Vincent Heart Center of Indiana was named one of 50 cardiovascular hospitals in the country by market research firm Thomson Reuters. According to the firm, 97 percent of all heart inpatients at U.S. hospitals survive their procedures and 96 percent remain complication free. Still, the top 50 hospitals have even better results, including 23 percent fewer deaths for bypass surgery patients, a 40-percent lower rate of heart failure complications, fewer readmissions, shorter hospital stays and costs that were lower by $4,200 per patient. Thomson Reuters based its analysis on data from the 2009 and 2010 Medicare Provider Analysis and Review, which includes nearly all senior patients. The St. Vincent Heart Center was the only Indianapolis hospital named to the list this year.
Eli Lilly and Co.’s experimental drug doubled levels of good cholesterol in a study, setting up a race with Merck & Co. and Roche Holding AG to develop a new class of medicines to lower heart risk.
Eli Lilly and Co. divorced one diabetes darling in favor of a new flame last week, but no analysts cheered. And a few booed.
A study showing Johnson & Johnson and Bayer AG’s blood-thinner Xarelto succeeded where rival drugs failed could give the companies entry to a $1 billion-plus market where Eli Lilly already competes.
The Indianapolis-based pharmaceutical firm claims an Australian veterinary clinic is infringing on its Comfortis flea medication’s trademark by reselling it to U.S. consumers online.
Endocyte employs 12 people in Indianapolis and plans to add three or four more commercial executives there over the next year and a half as it anticipates approval of its ovarian cancer medication in Europe.
